Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCure 51
About this trial
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival.
Patients with:
* Cohort A: metastatic pancreatic ductal adenocarcinoma * Cohort B: glioblastoma IDHwt * Cohort C: extensive small cell lung cancer
This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.
Eligibility criteria
Qualifiers
Adult patient (≥18 years old at diagnosis).
Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer.
Long-term survival is defined as an exceptionally long survival ≥ 5 years from stage IV diagnosis for PDAC, extensive SCLC, and ≥ 3 years for GBM-IDHwt.
One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual
Disqualifiers
<18 years old at diagnosis.
Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria.
Tumor sample not available or not reaching the required quality for multi-omic analyses.
Trial design
Treatments tested in this trial
- Long term survival multimodal analysis
Treatment groups
1,020 Participants
are divided into 3 treatment groupsSponsors and collaborators
Cure 51
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator
Centre Leon Berard
Collaborator
Vall d'Hebron Institute of Oncology
Collaborator
Istituto Europeo di Oncologia
Collaborator
Charite University, Berlin, Germany
Collaborator
Source ClinicalTrials.gov